XNK Therapeutics appoints Dr. Anna-Karin Maltais as CSO
XNK Therapeutics AB (“XNK”) today announced the appointment of Dr. Anna-Karin Maltais as Chief Scientific Officer, effective October 17[th]. She will be a member of the company’s management team.Anna-Karin Maltais, PhD, will be responsible for further developing and implementing XNK Therapeutics’ scientific strategy. She will lead a team responsible for research and innovation with focus on continuing the development of the company’s platform as well as improving the production processes and executing operational research plans. Dr. Maltais received her PhD. in immunobiology and tumor